D.-M. Zahm

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

"Anaphylactoid syndrome of pregnancy"

Michael Kretzschmar, D.-M. Zahm, K. Remmler et al. · Der Anaesthesist · 2003 · 33 citations

Medicine, Immunology, Obstetrics +11

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

Gϋnter von Minckwitz, Mahdi Rezai, Hans Tesch et al. · European Journal of Cancer · 2016 · 32 citations

Medicine, Oncology, Pharmacotherapy +17

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry

Elena Laakmann, Isabell Witzel, Tanja Neunhöffer et al. · ESMO Open · 2022 · 15 citations · Full text

Medicine, Neurology, Oncology +17